- Home
- ERJ vs EXEL Comparison
ERJ vs EXEL Comparison
Compare ERJ & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERJ
- EXEL
- Stock Information
- Founded
- ERJ 1969
- EXEL 1994
- Country
- ERJ Brazil
- EXEL United States
- Employees
- ERJ N/A
- EXEL N/A
- Industry
- ERJ Aerospace
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ERJ Industrials
- EXEL Health Care
- Exchange
- ERJ Nasdaq
- EXEL Nasdaq
- Market Cap
- ERJ 10.3B
- EXEL 10.4B
- IPO Year
- ERJ 2000
- EXEL 2000
- Fundamental
- Price
- ERJ $59.55
- EXEL $39.25
- Analyst Decision
- ERJ Buy
- EXEL Buy
- Analyst Count
- ERJ 6
- EXEL 22
- Target Price
- ERJ $60.60
- EXEL $44.00
- AVG Volume (30 Days)
- ERJ 1.1M
- EXEL 2.4M
- Earning Date
- ERJ 11-07-2025
- EXEL 10-28-2025
- Dividend Yield
- ERJ 0.08%
- EXEL N/A
- EPS Growth
- ERJ 11.89
- EXEL 81.76
- EPS
- ERJ 0.53
- EXEL 2.08
- Revenue
- ERJ $7,305,193,434.00
- EXEL $2,230,005,000.00
- Revenue This Year
- ERJ N/A
- EXEL $9.10
- Revenue Next Year
- ERJ $11.28
- EXEL $12.47
- P/E Ratio
- ERJ $111.44
- EXEL $18.88
- Revenue Growth
- ERJ 40.55
- EXEL 10.73
- 52 Week Low
- ERJ $32.89
- EXEL $27.86
- 52 Week High
- ERJ $62.09
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- ERJ 53.78
- EXEL 49.27
- Support Level
- ERJ $56.04
- EXEL $37.52
- Resistance Level
- ERJ $60.55
- EXEL $40.53
- Average True Range (ATR)
- ERJ 1.75
- EXEL 1.12
- MACD
- ERJ 0.01
- EXEL -0.08
- Stochastic Oscillator
- ERJ 59.71
- EXEL 40.90
About ERJ Embraer S.A.
Embraer SA based in Sao Paulo, Brazil, manufacturer of jets. Its focus is to achieve customer satisfaction with and services addressing the commercial airline, executive jets, and defense and security markets. It has developed a customer-centric technology-driven portfolio of commercial aviation products and services that allows it to build long-term relationships with clients in the commercial aviation, executive jets, and defense and security markets. It operates through the various segments namely Commercial Aviation, Defense and Security, Executive Aviation, Service and Support, and Other Segments. The company generates maximum revenue from the Commercial Aviation segment.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.